Prof. dr. M.J. van de Vijver MD PhD publications

foto

Publications Prof. dr. M.J. van de Vijver MD PhD

Position
Professor
Main activities
Patient care, Research
Specialisation
Pathology
Focus of research

 Genetic alterations and gene expression profiles of solid tumors

2018

  • Menezes GLG, Pijnappel RM, Meeuwis C, Bisschops R, Veltman J, Lavin PT, van de Vijver MJ, Mann RM, Downgrading of Breast Masses Suspicious for Cancer by Using Optoacoustic Breast Imaging. RADIOLOGY 2018;288 (2):355-365 [PubMed]
  • Sobral-Leite M, van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM, Severson TM, Mulligan AM, Weerasooriya N, Sanders J, Glas AM, Wehkamp D, Mittempergher L, Kersten K, Cimino-Mathews A, Peters D, Hooijberg E, Broeks A, van de Vijver MJ, Bernards R, Andrulis IL, Kok M, de Visser KE, Schmidt MK, BRCA1-like status, tumor-infiltrating immune cells and survival. ONCOIMMUNOLOGY 2018;7 (12):e1509820 [PubMed]
  • Soer E, Brosens L, van de Vijver M, Dijk F, van Velthuysen ML, Farina-Sarasqueta A, Morreau H, Offerhaus J, Koens L , Verheij J, Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens. VIRCHOWS ARCH 2018;472 (4):533-543 [PubMed]
  • Teepen JC, Kok JL, van Leeuwen FE, Tissing WJE, Dolsma WV, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, van den Berg MH, van der Heiden-van der Loo M, Hauptmann M, Jongmans MC, Overbeek LI, van de Vijver MJ, Kremer LCM, Ronckers CM, Aleman BMP, van den Berg MH, Bresters D, Caron HN, Daniels LA, Dolsma W, van Dulmen-den Broeder E, Grootenhuis MA, Haasbeek CJ, den Hartogh JG, Hauptmann M, van der Heiden-van der Loo M, van den Heuvel-Eibrink MM, Hollema N, Janssens GO, Jongmans MC, Jaspers MWM, Kok JL, Kremer LCM, van Leeuwen FE, Loonen J, Maduro JH, Neggers SJCMM, Oldenburger F, Overbeek LI, van der Pal HJ, Postma A, de Ridder-Sluiter JG, van Rij CM, Ronckers CM, Teepen JC , Tersteeg RJ, Tissing WJE, Versluys AB, van de Vijver MJ, Zsíros J, Colorectal Adenomas and Cancers After Childhood Cancer Treatment: A DCOG-LATER Record Linkage Study. JNCI-J NATL CANCER I 2018;110 (7):758 djx266-767 [PubMed]

2017

  • Creemers A, Krausz S, Strijker M, van der Wel MJ, Soer EC, Reinten RJ, Besselink MG, Wilmink JW, van de Vijver MJ, van Noesel CJM, Verheij J, Meijer SL, Dijk F, Bijlsma MF , van Oijen MGH, van Laarhoven HWM, Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. BBA-BIOENERGETICS 2017;1868 (2):394-403 [PubMed]
  • Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JWM, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S, HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. NAT MED 2017;23 (4):517-+ [PubMed]
  • Glodzik D, Morganella S, Davies H, Simpson PT, Li Y, Zou X, Diez-Perez J, Staaf J, Alexandrov LB, Smid M, Brinkman AB, Rye IH, Russnes H, Raine K, Purdie CA, Lakhani SR, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Viari A, Easton D, Evan G, Campbell PJ, Stratton MR, Nik-Zainal S, A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. NAT GENET 2017;49 (3):341-348 [PubMed]
  • Glodzik D, Morganella S, Davies H, Simpson PT, Li Y, Zou X, Diez-Perez J, Staaf J, Alexandrov LB, Smid M, Brinkman AB, Rye IH, Russnes H, Raine K, Purdie CA, Lakhani SR, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Viari A, Easton D, Evan G, Campbell PJ, Stratton MR, Nik-Zainal S, Corrigendum: A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. NAT GENET 2017;49 (11):1661 [PubMed]
  • Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, O'Meara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BKT, Caldas C, Tutt A, Ueno NT, van 't Veer LJ, Martens JWM, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale AL, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ, Stratton MR, Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. NATURE 2017;543 (7647):714-718 [PubMed]
  • Savci-Heijink CD, Halfwerk H, Koster J, van de Vijver MJ, Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer. BMC CANCER 2017;17 (1):755 [PubMed]
  • Smeenge M, Tranquart F, Mannaerts CK, de Reijke TM, van de Vijver MJ, Laguna MP, Pochon S, de La Rosette JJMCH, Wijkstra H, First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study. INVEST RADIOL 2017;52 (7):419-427 [PubMed]
  • van der Leij F. Optimizing treatment of low risk breast cancer patients. S.l.: s.n.; 2017. 163p. ISBN 978-94-6233-688-9 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam, onderzoek bij Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam. (Promotor(s): van de Vijver MJ; copromotor(s): Elkhuizen PHM, Bartelink H)

2016

  • Bosma SCJ, van der Leij F, van Werkhoven E, Bartelink H, Wesseling J, Linn S, Rutgers EJ, van de Vijver MJ, Elkhuizen PHM, Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period. BREAST CANCER RES TR 2016;156 (2):391-400 [PubMed]
  • Chen Y, van de Vijver MJ, Hibshoosh H, Parsons R, Saal LH, PTEN and NEDD4 in Human Breast Carcinoma. PATHOL ONCOL RES 2016;22 (1):41-47 [PubMed]
  • IJspeert JEG, Tutein Nolthenius CJ, Kuipers EJ, van Leerdam ME, Nio CY, Thomeer MGJ, Biermann K, van de Vijver MJ, Dekker E, Stoker J, CT-Colonography vs. Colonoscopy for Detection of High-Risk Sessile Serrated Polyps. AM J GASTROENTEROL 2016;111 (4):516-522 [PubMed]
  • McConechy MK, Färkkilä A, Horlings HM, Talhouk A, Unkila-Kallio L, van Meurs HS, Yang W, Rozenberg N, Andersson N, Zaby K, Bryk S, Bützow R, Halfwerk JBG, Hooijer GKJ, van de Vijver MJ, Buist MR, Kenter GG, Brucker SY, Krämer B, Staebler A, Bleeker MCG, Heikinheimo M, Kommoss S, Blake Gilks C, Anttonen M, Huntsman DG, Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. JNCI-J NATL CANCER I 2016;108 (11):djw134 [PubMed]
  • Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, Sieuwerts AM, Brinkman AB, Martin S, Ramakrishna M, Butler A, Kim HY, Borg Å, Sotiriou C, Futreal PA, Campbell PJ, Span PN, van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Sale J, Rada C, Stratton MR, Birney E, Nik-Zainal S, The topography of mutational processes in breast cancer genomes. NAT COMMUN 2016;7:11383 [PubMed]
  • Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR, Landscape of somatic mutations in 560 breast cancer whole-genome sequences. NATURE 2016;534 (7605):47-+ [PubMed]
  • Savci-Heijink CD, Halfwerk H, Koster J, van de Vijver MJ, A novel gene expression signature for bone metastasis in breast carcinomas. BREAST CANCER RES TR 2016;156 (2):249-259 [PubMed]
  • She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YKI, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, Saal LH, Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC CANCER 2016;16 (1):587 [PubMed]
  • Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-van der Smissen WJC, van der Vlugt-Daane M, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Meijer-van Gelder ME, van Deurzen CHM, MacGrogan G, van den Eynden GGGM, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JWM, Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. NAT COMMUN 2016;7:12910 [PubMed]
  • Tutein Nolthenius CJ, Boellaard TN, de Haan MC, Nio CY, Thomeer MGJ, Bipat S, Montauban van Swijndregt AD, van de Vijver MJ, Biermann K, Kuipers EJ, Dekker E, Stoker J, Computer tomography colonography participation and yield in patients under surveillance for 6-9 mm polyps in a population-based screening trial. EUR RADIOL 2016;26 (8):2762-2770 [PubMed]
  • van der Leij F, van Werkhoven E, Bosma S, Linn SC, Rutgers EJ, van de Vijver MJ, Bartelink H, Elkhuizen PHM, Scholten A, Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute. BREAST 2016;30:19-25 [PubMed]
  • van Rijssen LB, Rombouts SJE, Walma MS, Vogel JA, Tol JA, Molenaar IQ, van Eijck CHJ, Verheij J, van de Vijver MJ, Busch ORC, Besselink MGH, Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. SURG PATHOL CLIN 2016;9 (4):539-545 [PubMed]

2015

  • Damhofer H, Ebbing EA, Steins A, Welling L, Tol JA, Krishnadath KK, van Leusden T, van de Vijver MJ, Besselink MG, Busch OR, van Berge Henegouwen MI, van Delden O, Meijer SL, Dijk F, Medema JP, van Laarhoven HW, Bijlsma MF, Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. J TRANSL MED 2015;13 (1):115 [PubMed]
  • Dekker TJA, ter Borg S, Hooijer GKJ, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Bult P, Riemersma SA, van Deurzen CHM, Sleddens HFBM, Mesker WE, Kroep JR, Smit VTHBM, van de Vijver MJ, Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. BREAST CANCER RES TR 2015;152 (2):247-252 [PubMed]
  • Dekker TJA, ter Borg S, Hooijer GKJ, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Bult P, Riemersma SA, van Deurzen CHM, Sleddens HFBM, Mesker WE, Kroep JR, Smit VTHBM, van de Vijver MJ, Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach (vol 152, pg 247, 2015). BREAST CANCER RES TR 2015;152 (2):253 [PubMed]
  • Rutten MJ. Predictive factors in epithelial ovarian cancer: Towards individualized patient care. S.l.: s.n.; 2015. 198p. ISBN 978-94-6259-661-0 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Kenter GG, van de Vijver MJ; copromotor(s): Buist MR)
  • Savci-Heijink CD, Halfwerk H, Hooijer GKJ, Horlings HM, Wesseling J, van de Vijver MJ, Retrospective analysis of metastatic behaviour of breast cancer subtypes. BREAST CANCER RES TR 2015;150 (3):547-557 [PubMed]
  • Tan PH, Schnitt SJ, van de Vijver MJ, Ellis IO, Lakhani SR, Papillary and neuroendocrine breast lesions: the WHO stance. HISTOPATHOLOGY 2015;66 (6):761-770 [PubMed]
  • Tutein Nolthenius CJ, Boellaard TN, de Haan MC, Nio CY, Thomeer MGJ, Bipat S, Montauban van Swijndregt AD, van de Vijver MJ, Biermann K, Kuipers EJ, Dekker E, Stoker J, Evolution of Screen-Detected Small (6-9 mm) Polyps After a 3-Year Surveillance Interval: Assessment of Growth With CT Colonography Compared With Histopathology. AM J GASTROENTEROL 2015;110 (12):1682-1690 [PubMed]
  • van der Leij F, Bosma SCJ, van de Vijver MJ, Wesseling J, Vreeswijk S, Rivera S, Bourgier C, Garbay JR, Foukakis T, Lekberg T, van den Bongard DHJGD, van Vliet-Vroegindeweij C, Bartelink H, Rutgers EJ, Elkhuizen PHM, First results of the preoperative accelerated partial breast irradiation (PAPBI) trial. RADIOTHER ONCOL 2015;114 (3):322-327 [PubMed]

2014

  • Drukker CA, Nijenhuis MV, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Schmidt MK, van't Veer LJ, Sonke GS, Rutgers EJT, van de Vijver MJ, Linn SC, Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. BREAST CANCER RES TR 2014;145 (3):697-705 [PubMed]
  • Drukker CA, van Tinteren H, Schmidt MK, Rutgers EJT, Bernards R, van de Vijver MJ, van't Veer LJ, Long-term impact of the 70-gene signature on breast cancer outcome. BREAST CANCER RES TR 2014;143 (3):587-592 [PubMed]
  • Farazi TA, ten Hoeve JJ, Brown M, Mihailovic A, Horlings HM, van de Vijver MJ, Tuschl T, Wessels LFA, Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. GENOME BIOL 2014;15 (1):R9 [PubMed]
  • Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G, HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. MODERN PATHOL 2014;27 (1):4-18 [PubMed]
  • Hazewinkel Y, de Wijkerslooth TR, Stoop EM, Bossuyt PM, Biermann K, van de Vijver MJ, Fockens P, van Leerdam ME, Kuipers EJ, Dekker E, Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy. ENDOSCOPY 2014;46 (3):219-224 [PubMed]
  • Jiwa LS, van Diest PJ, Hoefnagel LD, Wesseling J, Wesseling P, Moelans CB [Contributors: van de Vijver MJ, van Slooten HJ, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van der Groep P, de Vries EGE, van der Wall E]] , Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC CANCER 2014;14:864 [PubMed]
  • Moelans CB, van der Groep P, Hoefnagel LDC, van de Vijver MJ, Wesseling P, Wesseling J, van der Wall E, van Diest PJ, Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. CANCER LETT 2014;344 (1):138-146 [PubMed]
  • Rutten MJ, Dijk F, Savci-Heijink CD, Buist MR, Kenter GG, van de Vijver MJ, Jordanova ES, HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas. J IMMUNOL RES 2014;2014:274584 [PubMed]
  • Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O'Meara S, Anderson E, Maddison M, Gamble S, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, van't Veer L, Caldas C, Desmedt C, Sotiriou C, Aparicio S, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL, van de Vijver M, Vincent-Salomon A, van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ [Contributors: Provenzano E, van de Vijver M, Richardson AL, Purdie C, Pinder S, MacGrogan G, Vincent-Salomon A, Larsimont D, Grabau D, Sauer T, Garred Ø, Ehinger A, van den Eynden GG, van Deurzen CHM, Salgado R, Brock JE, Lakhani SR, Giri DD, Arnould L, Jacquemier J, Treilleux I, Caldas C, Chin SF, Fatima A, Thompson AM, Stenhouse A, Foekens J, Martens J, Sieuwerts A, Brinkman A, Stunnenberg H, Span PN, Sweep F, Desmedt C, Sotiriou C, Thomas G, Broeks A, Langerod A, Aparicio S, Simpson P, van 't Veer L, Eyfjörd JE, Hilmarsdottir H, Jonasson JG, Børresen-Dale AL, Lee MTM, Wong BH, Tan BKT, Hooijer GKJ, Cooper C, Eeles R, Wedge D, van Loo P, Gundem G, Alexandrov L, Kremeyer B, Butler A, Lynch A, Edwards S, Camacho N, Massie C, Kote-Jarai Z, Dennis N, Merson S, Zamora J, Kay J, Corbishley C, Thomas S, Nik-Zainai S, O'Meara S, Matthews L, Clark J, Hurst R, Mithen R, Cooke S, Raine K, Jones D, Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison M, Gamble S, Greenman C, Berney D, Hazell S, Livni N, Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol D, Mayer E, Dudderidge T, Shah N, Gnanapragasam V, Campbell P, Futreal A, Easton D, Warren AY, Foster C, Stratton M, Whitaker H, McDermott U, Brewer D, Neal D]] , Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. SCIENCE 2014;345 (6196):531-+ [PubMed]
  • van de Vijver MJ, Molecular tests as prognostic factors in breast cancer. VIRCHOWS ARCH 2014;464 (3):283-291 [PubMed]

2013

  • de Boer P, Adam JA, Buist MR, van de Vijver MJ, Rasch CR, Stoker J, Bipat S, Stalpers LJA, Role of MRI in detecting involvement of the uterine internal os in uterine cervical cancer: systematic review of diagnostic test accuracy. EUR J RADIOL 2013;82 (9):e422-e428 [PubMed]
  • Dekker TJA, Smit VTHBM, Hooijer GKJ, van de Vijver MJ, Mesker WE, Tollenaar RAEM, Nortier JWR, Kroep JR, Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. ANN ONCOL 2013;24 (4):931-937 [PubMed]
  • Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Roumen RMH, Knauer M, van 't Veer LJ, Sonke GS, Rutgers EJT, van de Vijver MJ, Linn SC, A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. INT J CANCER 2013;133 (4):929-936 [PubMed]
  • Hoefnagel LDC, van der Groep P, van de Vijver MJ, Boers JE, Wesseling P, Wesseling J, van der Wall E, van Diest PJ, Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. ANN ONCOL 2013;24 (12):3017-3023 [PubMed]
  • Horlings HM, Weigelt B, Anderson EM, Lambros MB, Mackay A, Natrajan R, Ng CKY, Geyer FC, van de Vijver MJ, Reis-Filho JS, Genomic profiling of histological special types of breast cancer. BREAST CANCER RES TR 2013;142 (2):257-269 [PubMed]
  • Swank HA, Mulder IM, Hop WC, van de Vijver MJ, Lange JF, Bemelman WA, Routine histopathology for carcinoma in cholecystectomy specimens not evidence based: a systematic review. SURG ENDOSC 2013;27 (12):4439-4448 [PubMed]
  • van der Bij S, Baas P, van de Vijver MJ, de Mol BAJM, Burgers JA, Legal claims for malignant mesothelioma: dealing with all cases. LUNG CANCER 2013;80 (2):153-158 [PubMed]

2012

  • Dekker TJA, Borg ST, Hooijer GKJ, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Mesker WE, Kroep JR, Smit VTHBM, van de Vijver MJ, Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. BREAST CANCER RES 2012;14 (3):R93 [PubMed]
  • Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, van de Vijver M , Viale G, Loi S, Reis-Filho JS, Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. ANN ONCOL 2012;23 (12):2997-3006 [PubMed]
  • Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS, Functional characterization of the 19q12 amplicon in grade III breast cancers. BREAST CANCER RES 2012;14 (2):R53 [PubMed]
  • Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G, HER2 testing in gastric cancer: a practical approach. MODERN PATHOL 2012;25 (5):637-650 [PubMed]
  • Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, Sie D, Kerkhoven RM, Hupé P, Hadhri R, Fourquet A, Bartelink H, Barillot E, Sigal-Zafrani B, van de Vijver MJ, Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women. CLIN CANCER RES 2012;18 (6):1704-1715 [PubMed]
  • Stephens PJ, Tarpey PS, Davies H, van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerød A, Lee MTM, Shen CY, tee BTK, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van 't Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SAJR, Salomon AV, Børresen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, Stratton MR [Contributors: Karesen R, Schlichting E, Naume B, Sauer T, Ottestad L]] , The landscape of cancer genes and mutational processes in breast cancer. NATURE 2012;486 (7403):400-+ [PubMed]
  • Stoop EM, de Haan MC, de Wijkerslooth TR, Bossuyt PM, van Ballegooijen M, Nio CY, van de Vijver MJ, Biermann K, Thomeer M, van Leerdam ME, Fockens P, Stoker J, Kuipers EJ, Dekker E, Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. LANCET ONCOL 2012;13 (1):55-64 [PubMed]
  • Tanis E, van de Velde CJH, Bartelink H, van de Vijver MJ, Putter H, van der Hage JA, Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. EUR J CANCER 2012;48 (12):1751-1756 [PubMed]
  • van der Bij S, Koffijberg H, Burgers JA, Baas P, van de Vijver MJ, de Mol BAJM, Moons KGM, Prognosis and prognostic factors of patients with mesothelioma: a population-based study. BRIT J CANCER 2012;107 (1):161-164 [PubMed]
  • van der Leij F, Elkhuizen PHM, Bartelink H, van de Vijver MJ, Predictive Factors for Local Recurrence in Breast Cancer. SEMIN RADIAT ONCOL 2012;22 (2):100-107 [PubMed]
  • van Vliet MH, Horlings HM, van de Vijver MJ, Reinders MJT, Wessels LFA, Integration of Clinical and Gene Expression Data Has a Synergetic Effect on Predicting Breast Cancer Outcome. PLOS ONE 2012;7 (7):e40358 [PubMed]

2011

  • Beck AH, Sangoi AR, Leung S, Marinelli RJ, Nielsen TO, van de Vijver MJ, West RB, van de Rijn M, Koller D, Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. SCI TRANSL MED 2011;3 (108):108ra113 [PubMed]
  • Bueno-de-Mesquita JM, Sonke GS, van de Vijver MJ, Linn SC, Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. ANN ONCOL 2011;22 (9):2021-2030 [PubMed]
  • de Sousa E Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP, Rodermond H, Dekker E, van der Loos CM, Pals ST, van de Vijver MJ, Versteeg R, Richel DJ, Vermeulen L, Medema JP, Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. CELL STEM CELL 2011;9 (5):476-485 [PubMed]
  • Farazi TA, Horlings HM, ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyal F, van Kouwenhove M, Kreike B, Sie D, Hovestadt V, Wessels LFA, van de Vijver MJ, Tuschl T, MicroRNA sequence and expression analysis in breast tumors by deep sequencing. CANCER RES 2011;71 (13):4443-4453 [PubMed]
  • Hajage D, de Rycke Y, Bollet M, Savignoni A, Caly M, Pierga JY, Horlings HM, van de Vijver MJ, Vincent-Salomon A, Sigal-Zafrani B, Senechal C, Asselain B, Sastre X, Reyal F, External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement. PLOS ONE 2011;6 (11):e27446 [PubMed]
  • Hartog H, Horlings HM, van der Vegt B, Kreike B, Ajouaou A, van de Vijver MJ, Marike Boezen H, de Bock GH, van der Graaf WTA, Wesseling J, Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. BREAST CANCER RES TR 2011;129 (3):725-736 [PubMed]
  • Horlings HM. Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling. s.l.: s.n.; 2011. 191p. ISBN 9789077713921 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van de Vijver MJ; copromotor(s): )
  • Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, Horlings HM, Shah N, Umbricht C, Wang P, Wang Y, Kong B, Langerød A, Børresen-Dale AL, Kim SK, van de Vijver M, Sukumar S, Whitfield ML, Kellis M, Xiong Y, Wong DJ, Chang HY, Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. NAT GENET 2011;43 (7):621-629 [PubMed]
  • Kreike B. Gene expression profiling of breast cancer to identify subtypes and to predict local recurrence after breast conserving therapy. s.l.: s.n.; 2011. 121p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van de Vijver MJ, Bartelink GMM; copromotor(s): )
  • Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MTFD, van de Vijver MJ, Wesseling J, Nederlof PM, Rodenhuis S, Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. ANN ONCOL 2011;22 (4):870-876 [PubMed]
  • Meijer SL, Wesseling J, Smit VT, Nederlof PM, Hooijer GKJ, Ruijter H, Arends JW, Kliffen M, van Gorp JM, Sterk L, van de Vijver MJ, HER2 gene amplification in patients with breast cancer with equivocal IHC results. J CLIN PATHOL 2011;64 (12):1069-1072 [PubMed]
  • Sanz-Pamplona R, Aragüés R, Driouch K, Martín B, Oliva B, Gil M, Boluda S, Fernández PL, Martínez A, Moreno V, Acebes JJ, Lidereau R, Reyal F, van de Vijver MJ, Sierra A, Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors. AM J PATHOL 2011;179 (2):564-579 [PubMed]
  • van der Hage JA, Mieog JSD, van de Velde CJH, Putter H, Bartelink H, van de Vijver MJ, Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials. BREAST CANCER RES 2011;13 (3):R68 [PubMed]
  • van der Zaag ES, Welling L, Peters HM, van de Vijver MJ, Bemelman WA, Buskens CJ, Indeling occulte tumorcellen in de lymfklieren bij patiënten met darmkanker onvoldoende betrouwbaar. NED TIJDSCHR GENEESKD 2011;155 (7):A2697 [PubMed]
  • van Nes JGH, de Kruijf EM, Faratian D, van de Velde CJH, Putter H, Falconer C, Smit VTHBM, Kay C, van de Vijver MJ, Kuppen PJK, Bartlett JMS, COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. BREAST CANCER RES TR 2011;125 (3):671-685 [PubMed]
  • Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC, An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. ANN ONCOL 2011;22 (7):1561-1570 [PubMed]
  • Zonderland HM, van de Vijver MJ, Visser M, Mammadiagnostiek: integratie pathologie en radiologie. NED TIJDSCHR GENEESKD 2011;155 (18):A2967 [PubMed]

2010

  • Bilous M, Osamura RY, Rüschoff J, van de Vijver M, Hanna W, Penault-Llorca F, Roche P, HER-2 amplification is highly homogenous in gastric cancer. HUM PATHOL 2010;41 (2):304-5; author reply 305-6 [PubMed]
  • Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L, Fourquet A, Gee J, Holli K, Jakesz R, Kerin M, Mansel R, Nicholson R, Pienkowski T, Pinder S, Sundquist M, van de Vijver M , Ellis I, ONCOPOOL - a European database for 16,944 cases of breast cancer. EUR J CANCER 2010;46 (1):56-71 [PubMed]
  • Broeks A, Braaf LM, Wessels LFA, van de Vijver M, de Bruin ML, Stovall M, Russell NS, van Leeuwen FE, van 't Veer LJ, Radiation-associated breast tumors display a distinct gene expression profile. INT J RADIAT ONCOL 2010;76 (2):540-547 [PubMed]
  • Bueno-de-Mesquita JM, Nuyten DSA, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ, The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. ANN ONCOL 2010;21 (1):40-47 [PubMed]
  • de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJTFD, Wesseling J, van de Vijver M, Wessels LFA, Rodenhuis S, Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. BREAST CANCER RES TR 2010;119 (1):119-126 [PubMed]
  • Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY, Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. NATURE 2010;464 (7291):1071-U148 [PubMed]
  • Hoefnagel LDC, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van der Groep P, de Vries EGE, van der Wall E, van Diest PJ, Receptor conversion in distant breast cancer metastases. BREAST CANCER RES 2010;12 (5):R75 [PubMed]
  • Holstege H, Horlings HM, Velds A, Langerod A, Borresen-Dale AL, van de Vijver MJ, Nederlof PM, Jonkers J, BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC CANCER 2010;10 (1):654 [PubMed]
  • Horlings HM, Lai C, Nuyten DSA, Halfwerk H, Kristel P, van Beers E, Joosse SA, Klijn C, Nederlof PM, Reinders MJT, Wessels LFA, van de Vijver MJ, Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients. CLIN CANCER RES 2010;16 (2):651-663 [PubMed]
  • Horlings HM, Savci-Heijink CD, van de Vijver MJ, Translating the Genomic Architecture of Breast Cancer into Clinical Applications. SCI TRANSL MED 2010;2 (38):38ps32 [PubMed]
  • Knauer M, Mook S, Rutgers EJT, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RHT, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ, The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. BREAST CANCER RES TR 2010;120 (3):655-661 [PubMed]
  • Kreike B, Hart G, Bartelink H, van de Vijver MJ, Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations. BREAST CANCER RES TR 2010;122 (3):711-720 [PubMed]
  • Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJT, van 't Veer LJ, The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. ANN ONCOL 2010;21 (4):717-722 [PubMed]
  • Nuyten DSA. Hypothesis driven gene expression profiling in breast cancer. s.l: s.n.; 2010. -p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van de Vijver MJ, Bartelink GMM; copromotor(s): )
  • Rodenhuis S, Mandjes IAM, Wesseling J, van de Vijver MJ, Peeters MJTDFV, Sonke GS, Linn SC, A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. ANN ONCOL 2010;21 (3):481-487 [PubMed]
  • Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJT, Vrancken Peeters MJTFD, van Tinteren H, van't Veer LJ, Rodenhuis S, The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. BREAST CANCER RES TR 2010;119 (3):551-558 [PubMed]
  • Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A, Ashworth A, van de Vijver MJ, Reis-Filho JS, Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. ONCOGENE 2010;29 (14):2013-2023 [PubMed]
  • van der Zaag ES, Kooij N, van de Vijver MJ, Bemelman WA, Peters HM, Buskens CJ, Diagnosing occult tumour cells and their predictive value in sentinel nodes of histologically negative patients with colorectal cancer. EJSO-EUR J SURG ONC 2010;36 (4):350-357 [PubMed]
  • [Contributors: Hudson TJ, Anderson W, Aretz A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusuda J, Lane DP, Laplace F, Lu Y, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MMF, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SOM, Joly Y, Kato K, Kennedy KL, Nicolás P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clément B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, van de Vijver M, Futreal PA, Aburatani H, Bayés M, Bowtell DDL, Campbell PJ, Estivill X, Grimmond SM, Gut I, Hirst M, López-Otín C, Majumder P, Marra M, McPherson JD, Ning Z, Puente XS, Ruan Y, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Flicek P, Getz G, Guigó R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, López-Bigas N, Luo R, Muthuswamy L, Ouellette BFF, Pearson JV, Quesada V, Raphael BJ, Sander C, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Lathrop M, Thomas G, Yoshida T, Axton M, Gunter C, Miller LJ, Zhang J, Haider SA, Wang J, Yung CK, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Chalmers DRC, Hasel KW, Kaan TSH, Lowrance WW, Masui T, Rodriguez LL, Vergely C, Cloonan N, Defazio A, Eshleman JR, Etemadmoghadam D, Gardiner BA, Kench JG, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, DePinho RA, Thayer S, Shazand K, Beck T, Sam M, Timms L, Ballin V, Ji J, Zhang X, Chen F, Hu X, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevad L, Prokhortchouk E, Banks RE, Uhlén M, Viksna J, Ponten F, Skryabin K, Birney E, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, van't Veer L, Birnbaum D, Blanche H, Boucher P, Boyault S, Masson-Jacquemier JD, Pauporté I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Treilleux I, Bioulac-Sage P, Decaens T, Franco D, Gut M, Samuel D, Zucman-Rossi J, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Pederzoli P, Lawlor RT, Delledonne M, Bardelli A, Gress T, Klimstra D, Zamboni G, Nakamura Y, Miyano S, Fujimoto A, Campo E, de Sanjosé S, Montserrat E, González-Díaz M, Jares P, Himmelbaue H, Bea S, Aparicio S, Easton DF, Collins FS, Compton CC, Lander ES, Burke W, Green AR, Hamilton SR, Kallioniemi OP, Ley TJ, Liu ET, Wainwright BJ]] , International network of cancer genome projects. NATURE 2010;464 (7291):993-998 [PubMed]

2009

  • Bos PD, Zhang XHF, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J, Genes that mediate breast cancer metastasis to the brain. NATURE 2009;459 (7249):1005-U137 [PubMed]
  • Bueno-de-Mesquita JM. Who needs adjuvant systematic treatment? Predicting prognosis in node-negative breast cancer; from bench to bedside. s.l.: s.n.; 2009. 183p. ISBN 9789090242934 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van de Vijver MJ, Rodenhuis S; copromotor(s): Linn SC)
  • Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DSA, van Krimpen C, Meijers C, de Graaf PW, Bos MMEM, Hart AAM, Rutgers EJT, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, van't Veer LJ, van de Vijver MJ, Validation of 70-gene prognosis signature in node-negative breast cancer. BREAST CANCER RES TR 2009;117 (3):483-495 [PubMed]
  • Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R, Molecular profiles of progesterone receptor loss in human breast tumors. BREAST CANCER RES TR 2009;114 (2):287-299 [PubMed]
  • Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, Veltkamp SC, Nuyten DSA, Bartelink H, van de Vijver MJ, Local Recurrence after Breast-Conserving Therapy in Relation to Gene Expression Patterns in a Large Series of Patients. CLIN CANCER RES 2009;15 (12):4181-4190 [PubMed]
  • Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Rüschoff J, Osamura RY, Bilous M, Dowsett M, Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J CLIN ONCOL 2009;27 (10):1694-1705 [PubMed]
  • Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP, Yang ZQ, Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. ONCOGENE 2009;28 (50):4491-4500 [PubMed]
  • Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, van de Vijver M, Emerging technologies for assessing HER2 amplification. AM J CLIN PATHOL 2009;132 (4):539-548 [PubMed]
  • Retèl VP, Bueno-de-Mesquita JM, Hummel MJM, van de Vijver MJ, Douma KFL, Karsenberg K, van Dam FSAM, van Krimpen C, Bellot FE, Roumen RMH, Linn SC, van Harten WH, Constructive Technology Assessment (CTA) as a tool in Coverage with Evidence Development: The case of the 70-gene prognosis signature for breast cancer diagnostics. INT J TECHNOL ASSESS 2009;25 (1):73-83 [PubMed]
  • Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, Bender R, Linn SC, Glas AM, van de Vijver MJ, Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer. CLIN CANCER RES 2009;15 (22):7003-7011 [PubMed]
  • Russell NS, Kunkler IH, van Tienhoven G, Canney PA, Thomas J, Bartlett J, van de Vijver MJ, Belkacemi Y, Yarnold JR, Barrett-Lee PJ, Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?. J CLIN ONCOL 2009;27 (6):996-997 [PubMed]
  • Stein T, Salomonis N, Nuyten DSA, van de Vijver MJ, Gusterson BA, A mouse mammary gland involution mRNA signature identifies biological pathways potentially associated with breast cancer metastasis. J MAMMARY GLAND BIOL 2009;14 (2):99-116 [PubMed]
  • van Nes JGH, Putter H, Julien JP, Tubiana-Hulin M, van de Vijver M, Bogaerts J, de Vos M, van de Velde CJH, Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. BREAST CANCER RES TR 2009;115 (1):101-113 [PubMed]
  • Wertheim GBW, Yang TW, Pan TC, Ramne A, Liu Z, Gardner HP, Dugan KD, Kristel P, Kreike B, van de Vijver MJ, Cardiff RD, Reynolds C, Chodosh LA, The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis. P NATL ACAD SCI USA 2009;106 (37):15855-15860 [PubMed]

2008

  • Hannemann J. Gene expression profiling in breast cancer . A link between biology and clinical decision making. s.l.: s.n.; 2008. 130p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van de Vijver MJ, Rodenhuis S; copromotor(s): )
  • Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M , Kim W, Ochiai A, Rüschoff J, Henkel T, Assessment of a HER2 scoring system for gastric cancer: results from a validation study. HISTOPATHOLOGY 2008;52 (7):797-805 [PubMed]
  • Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, Noh DY, Salari K, Joosse SA, Reyal F, Lingjaerde OC, Kristensen VN, Børresen-Dale AL, Pollack J, van de Vijver MJ, ESR1 gene amplification in breast cancer: a common phenomenon?. NAT GENET 2008;40 (7):807-8; author reply 810-2 [PubMed]
  • Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, van de Vijver M, Berns A, A conditional mouse model for malignant mesothelioma. CANCER CELL 2008;13 (3):261-271 [PubMed]
  • Kreike B, Hart AAM, van de Velde T, Borger J, Peterse H, Rutgers E, Bartelink H, van de Vijver MJ, Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. INT J RADIAT ONCOL 2008;71 (4):1014-1021 [PubMed]
  • Linn SC, Bueno-de-Mesquita JM, van de Vijver MJ, Are gene signatures better than traditional clinical factors? - Authors' reply. LANCET ONCOL 2008;9 (3):198-199 [PubMed]
  • Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hannemann J, Muller SH, Peeters MJV, Gilhuijs KGA, Dynamic Contrast-Enhanced MRI for Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: Initial Results. AM J ROENTGENOL 2008;191 (5):1331-1338 [PubMed]
  • Meijnen P, Peterse JL, Antonini N, Rutgers EJT, van de Vijver MJ, Immunohistochemical categorisation of ductal carcinoma in situ of the breast. BRIT J CANCER 2008;98 (1):137-142 [PubMed]
  • Nuyten DSA, Hastie T, Chi JTA, Chang HY, van de Vijver MJ, Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. EUR J CANCER 2008;44 (15):2319-2329 [PubMed]
  • Nuyten DSA, van de Vijver MJ, Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity. SEMIN RADIAT ONCOL 2008;18 (2):105-114 [PubMed]
  • Pietersen AM, Horlings HM, Hauptmann M, Langerod A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, van de Vijver MJ, van Lohuizen M, EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. BREAST CANCER RES 2008;10 (6):R109 [PubMed]
  • Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LFA, A comprehensive analysis of prognostic signatures reveals the high predictive capacity of Proliferation, Immune response and RNA splicing modules in breast cancer. BREAST CANCER RES 2008;10 (6):R93 [PubMed]
  • Riegman PHJ, Bosch AL [Contributors: Riegman PHJ, Dinjens WNM, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van Damme B, van de Vijver M , van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Bosch AL, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Jaminé D, Passioukov A, Lejeune S, Therasse P, van Veen EB, Lam KH, Oosterhuis JW]] , OECI TuBaFrost tumor biobanking. TUMORI 2008;94 (2):160-163 [PubMed]
  • Starmans MHW, Krishnapuram B, Steck H, Horlings H, Nuyten DSA, van de Vijver MJ, Seigneuric R, Buffa FM, Harris AL, Wouters BG, Lambin P, Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. BRIT J CANCER 2008;99 (11):1884-1890 [PubMed]
  • Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT, An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. CANCER RES 2008;68 (15):6084-6091 [PubMed]
  • van Vliet MH, Reyal F, Horlings HM, van de Vijver MJ, Reinders MJT, Wessels LFA, Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC GENOMICS 2008;9 (1):375 [PubMed]
  • Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DSA, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, van de Vijver MJ, Minn AJ, An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. P NATL ACAD SCI USA 2008;105 (47):18490-18495 [PubMed]
  • Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LFA, de Jong D, van de Vijver MJ, van't Veer LJ, Peterse JL, Refinement of breast cancer classification by molecular characterization of histological special types. J PATHOL 2008;216 (2):141-150 [PubMed]
  • Wong DJ, Nuyten DSA, Regev A, Lin M, Adler AS, Segal E, van de Vijver MJ, Chang HY, Revealing targeted therapy for human cancer by gene module maps. CANCER RES 2008;68 (2):369-378 [PubMed]

2007

  • Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. CANCER CELL 2007;12 (4):395-402 [PubMed]
  • Bueno-de-Mesquita JM, van Harten WH, Retel VP, van't Veer LJ, van Dam FSAM, Karsenberg K, Douma KFL, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJT, Brink G, Floore AN, Glas AM, Roumen RMH, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC, Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). LANCET ONCOL 2007;8 (12):1079-1087 [PubMed]
  • Chi JT, Rodriguez EH, Wang Z, Nuyten DSA, Mukherjee S, van de Rijn M, van de Vijver MJ, Hastie T, Brown PO, Gene expression programs of human smooth muscle cells: tissue-specific differentiation and prognostic significance in breast cancers. PLOS GENET 2007;3 (9):1770-1784 [PubMed]
  • Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ, Standardization of HER2 testing: results of an international proficiency-testing ring study. MODERN PATHOL 2007;20 (5):584-591 [PubMed]
  • Kreike B, van de Vijver MJ, Are triple-negative tumours and basal-like breast cancer synonymous? Authors' response. BREAST CANCER RES 2007;9 (6):405 [PubMed]
  • Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ, Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. BREAST CANCER RES 2007;9 (5):R65 [PubMed]
  • Lai C, Horlings HM, van de Vijver MJ, van Beers EH, Nederlof PM, Wessels LFA, Reinders MJT, SIRAC: Supervised Identification of Regions of Aberration in aCGH datasets. BMC BIOINFORMATICS 2007;8:422 [PubMed]
  • Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, Foekens JA, van de Vijver M, Massagué J, Lung metastasis genes couple breast tumor size and metastatic spread. P NATL ACAD SCI USA 2007;104 (16):6740-6745 [PubMed]
  • van der Hage JA, Mieog JSD, van de Vijver MJ, van de Velde CJH, Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. BREAST CANCER RES 2007;9 (5):R70 [PubMed]
  • van de Vijver MJ, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Ruschoff J, Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. BREAST CANCER RES 2007;9 (5):R68 [PubMed]
  • van Zandwijk N, van de Vijver MJ, Clairvoyance or reliable prediction of the future?. ANN ONCOL 2007;18 (3):407-408 [PubMed]
  • Welm AL, Sneddon JB, Taylor C, Nuyten DSA, van de Vijver MJ, Hasegawa BH, Bishop JM, The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. P NATL ACAD SCI USA 2007;104 (18):7570-7575 [PubMed]
  • Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J CLIN ONCOL 2007;25 (1):118-145 [PubMed]
  • Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. ARCH PATHOL LAB MED 2007;131 (1):18-43 [PubMed]

2006

  • Abdullah-Sayani A, Bueno-de-Mesquita JM, van de Vijver MJ, Technology Insight: tuning into the genetic orchestra using microarrays--limitations of DNA microarrays in clinical practice. NAT CLIN PRACT ONCOL 2006;3 (9):501-516 [PubMed]
  • Adler AS, Lin M, Horlings H, Nuyten DSA, van de Vijver MJ, Chang HY, Genetic regulators of large-scale transcriptional signatures in cancer. NAT GENET 2006;38 (4):421-430 [PubMed]
  • Chi JT, Wang Z, Nuyten DSA, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO, Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLOS MED 2006;3 (3):e47 [PubMed]
  • Green JA, Berns EMJJ, Coens C, van Luijk I, Thompson-Hehir J, van Diest P, Verheijen RHM, van de Vijver M , van Dam P, Kenter GG, Tjalma W, Ewing PC, Teodorovic I, Vergote I, van der Burg MEL, Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). EUR J CANCER 2006;42 (15):2539-2548 [PubMed]
  • Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QGCM, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EGE, Rodenhuis S, van de Vijver MJ, Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. BRIT J CANCER 2006;95 (10):1334-1341 [PubMed]
  • Hannemann J, Velds A, Halfwerk JBG, Kreike B, Peterse JL, van de Vijver MJ, Classification of ductal carcinoma in situ by gene expression profiling. BREAST CANCER RES 2006;8 (5):R61 [PubMed]
  • Isabelle M, Teodorovic I, Morente MM, Jaminé D, Passioukov A, Lejeune S, Therasse P, Dinjens WNM, Oosterhuis JW, Lam KH, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van de Vijver M , van Boven H, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, Carbone A, Gloghini A, van Veen EB, van Damme B, Riegman PHJ, TuBaFrost 5: multifunctional central database application for a European tumor bank. EUR J CANCER 2006;42 (18):3103-3109 [PubMed]
  • Isabelle M, Teodorovic I, Oosterhuis JW, Riegman PHJ, Passioukov A, Lejeune S, Therasse P, Dinjens WNM, Lam KH, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van Damme B, van de Vijver M , van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, López-Guerrero JA, Llombart-Bosch A, Carbone A, Gloghini A, van Veen EB, Virtual microscopy in virtual tumor banking. ADV EXP MED BIOL 2006;587:75-86 [PubMed]
  • Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, van de Vijver MJ, Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. CLIN CANCER RES 2006;12 (19):5705-5712 [PubMed]
  • Lopez-Guerrero JA, Riegman PHJ, Oosterhuis JW, Lam KH, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van Damme B, van de Vijver M , van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Passioukov A, Lejeune S, Therasse P, van Veen EB, Dinjens WNM, Llombart-Bosch A, TuBaFrost 4: access rules and incentives for a European tumour bank. EUR J CANCER 2006;42 (17):2924-2929 [PubMed]
  • Morente MM, Mager R, Alonso S, Pezzella F, Spatz A, Knox K, Kerr D, Dinjens WNM, Oosterhuis JW, Lam KH, Oomen MHA, van Damme B, van de Vijver M , van Boven H, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Passioukov A, Lejeune S, Therasse P, van Veen EB, Ratcliffe C, Riegman PHJ, TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network. EUR J CANCER 2006;42 (16):2684-2691 [PubMed]
  • Nuyten DSA, Kreike B, Hart AAM, Chi JTA, Sneddon JB, Wessels LFA, Peterse HJ, Bartelink H, Brown PO, Chang HY, van de Vijver MJ, Predicting a local recurrence after breast-conserving therapy by gene expression profiling. BREAST CANCER RES 2006;8 (5):R62 [PubMed]
  • Nuyten DSA, van de Vijver MJ, Gene expression signatures to predict the development of metastasis in breast cancer. BREAST DIS 2006;26:149-156 [PubMed]
  • Riegman PHJ, Dinjens WNM, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van Damme B, van de Vijver M , van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Jaminé D, Passioukov A, Lejeune S, Therasse P, van Veen EB, Lam KH, Oosterhuis JW, TuBaFrost 1: Uniting local frozen tumour banks into a European network: an overview. EUR J CANCER 2006;42 (16):2678-2683 [PubMed]
  • Riegman PHJ, Oomen MHA, Dinjens WNM, Oosterhuis JW, Lam KH, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van Damme B, van de Vijver M , van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, López-Guerrero JA, Llombart-Bosch A, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Passioukov A, Lejeune S, Therasse P, van Veen EB, TuBaFrost: European virtual tumor tissue banking. ADV EXP MED BIOL 2006;587:65-74 [PubMed]
  • Rodenhuis S, Bontenbal M, van Hoesel QGCM, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, van Tinteren H, Peterse JL, van de Vijver MJ, de Vries EGE, Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. ANN ONCOL 2006;17 (4):588-596 [PubMed]
  • Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, van de Vijver MJ, Bergh J, Piccart M, Delorenzi M, Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. JNCI-J NATL CANCER I 2006;98 (4):262-272 [PubMed]
  • Teodorovic I, Isabelle M, Carbone A, Passioukov A, Lejeune S, Jaminé D, Therasse P, Gloghini A, Dinjens WNM, Lam KH, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, van Damme B, van de Vijver M , van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, van Veen EB, Oosterhuis JW, Riegman PHJ, TuBaFrost 6: virtual microscopy in virtual tumour banking. EUR J CANCER 2006;42 (18):3110-3116 [PubMed]
  • van Veen EB, Riegman PHJ, Dinjens WNM, Lam KH, Oomen MHA, Spatz A, Mager R, Ratcliffe C, Knox K, Kerr D, van Damme B, van de Vijver M , van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Llombart Bosch A, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Passioukov A, Lejeune S, Therasse P, Oosterhuis JW, TuBaFrost 3: regulatory and ethical issues on the exchange of residual tissue for research across Europe. EUR J CANCER 2006;42 (17):2914-2923 [PubMed]

2005

  • Chang HY, Nuyten DSA, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ, Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. P NATL ACAD SCI USA 2005;102 (10):3738-3743 [PubMed]
  • Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S, A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. CANCER RES 2005;65 (10):4059-4066 [PubMed]
  • Faneyte IF. Markers for effectiveness of chemotherapy and drug resistance in breast cancer. S.l.: s.n.; 2005. 162p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Rodenhuis S; copromotor(s): van de Vijver MJ)
  • Hannemann J, Oosterkamp HM, Bosch CAJ, Velds A, Wessels LFA, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ, Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J CLIN ONCOL 2005;23 (15):3331-3342 [PubMed]
  • van de Vijver M, Gene-expression profiling and the future of adjuvant therapy. ONCOLOGIST 2005;10 (Suppl. 2):30-34 [PubMed]
  • van de Vijver MJ, Biological variables and prognosis of DCIS. BREAST 2005;14 (6):509-519 [PubMed]
  • Voogd AC, van Oost FJ, Rutgers EJT, Elkhuizen PHM, van Geel AN, Scheijmans LJEE, van der Sangen MJC, Botke G, Hoekstra CJ, Jobsen JJ, van de Velde CJH, von Meyenfeldt MF, Tabak JM, Peterse JL, van de Vijver MJ, Coebergh JWW, van Tienhoven G, Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. EUR J CANCER 2005;41 (17):2637-2644 [PubMed]
  • West RB, Nuyten DSA, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M, Determination of stromal signatures in breast carcinoma. PLOS BIOL 2005;3 (6):e187 [PubMed]

2004

  • Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Kristel PMP, Taminiau AHM, Nooij M, Egeler RM, Hogendoorn PCW, Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. EUR J CANCER 2004;40 (7):963-970 [PubMed]
  • Cleton-Jansen AM, Buerger H, ter Haar N, Philippo K, van de Vijver MJ, Boecker W, Smit VTHBM, Cornelisse CJ, Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. GENE CHROMOSOME CANC 2004;41 (2):109-116 [PubMed]
  • Cleton-Jansen AM, Timmerman MC, van de Vijver MJ, van Asperen CJ, Kroon HM, Eilers PHC, Hogendoorn PCW, A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient. LAB INVEST 2004;84 (2):191-202 [PubMed]
  • Faneyte IF, Kristel PMP, van de Vijver MJ, Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. ANTICANCER RES 2004;24 (5A):2931-2939 [PubMed]
  • Faneyte IF, Peterse JL, van Tinteren H, Pronk C, Bontenbal M, Beex LVAM, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, ten Vergert EM, de Vries EGE, Rodenhuis S, van de Vijver MJ, Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. CLIN CANCER RES 2004;10 (13):4457-4463 [PubMed]
  • Olivier RI, van Beurden M, Lubsen MAC, Rookus MA, Mooij TM, van de Vijver MJ, van't Veer LJ, Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. BRIT J CANCER 2004;90 (8):1492-1497 [PubMed]
  • Perez EA, Pusztai L, van de Vijver M, Improving patient care through molecular diagnostics. SEMIN ONCOL 2004;31 (5 Suppl 10):14-20 [PubMed]
  • van der Hage JA, van den Broek LJCM, Legrand C, Clahsen PC, Bosch CJA, Robanus-Maandag EC, van de Velde CJH, van de Vijver MJ, Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. BRIT J CANCER 2004;90 (8):1543-1550 [PubMed]

2003

  • Baas P, Ardizzoni A, Grossi F, Nackaerts K, Numico G, van Marck E, van de Vijver M , Monetti F, Smid-Geirnaerdt MJA, van Zandwijk N, Debruyne C, Legrand C, Giaccone G, The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). EUR J CANCER 2003;39 (3):353-357 [PubMed]
  • Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G, van de Vijver M, Current perspectives on HER2 testing: a review of national testing guidelines. MODERN PATHOL 2003;16 (2):173-182 [PubMed]
  • Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M , Macgrogan G, Shepherd L, Amaral N, Duval C, Drijkoningen R, Larsimont D, Piccart M, Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?. ANN ONCOL 2003;14 (3):406-413 [PubMed]
  • Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ, Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. BRIT J CANCER 2003;88 (3):406-412 [PubMed]
  • Robanus-Maandag EC, Bosch CAJ, Kristel PM, Hart AAM, Faneyte IF, Nederlof PM, Peterse JL, van de Vijver MJ, Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J PATHOL 2003;201 (1):75-82 [PubMed]
  • van de Vijver MJ, Peterse H, The diagnosis and management of pre-invasive breast disease: pathological diagnosis--problems with existing classifications. BREAST CANCER RES 2003;5 (5):269 [PubMed]
  • van Ruth S, Acherman YIZ, van de Vijver MJ, Hart AAM, Verwaal VJ, Zoetmulder FAN, Pseudomyxoma peritonei: a review of 62 cases. EJSO-EUR J SURG ONC 2003;29 (8):682-688 [PubMed]
  • van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Bernards R, Friend SH, Expression profiling predicts outcome in breast cancer. BREAST CANCER RES 2003;5 (1):57-58 [PubMed]

2002

  • Faneyte IF, Kristel PMP, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JHM, van de Vijver MJ, Expression of the breast cancer resistance protein in breast cancer. CLIN CANCER RES 2002;8 (4):1068-1074 [PubMed]
  • Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF, The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J CLIN ONCOL 2002;20 (9):2310-2318 [PubMed]
  • Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JL, van de Vijver MJ, Dalesio O, van Tinteren H, Rutgers EJT, Richel DJ, Rodenhuis S, Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. ANN ONCOL 2002;13 (5):689-698 [PubMed]
  • Spermon JR, Roeleveld TA, van der Poel HG, Hulsbergen-van de Kaa CA, ten Bokkel Huinink WW, van de Vijver M , Witjes JA, Horenblas S, Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. UROLOGY 2002;59 (6):923-929 [PubMed]
  • van de Vijver M, Emerging technologies for HER2 testing. ONCOLOGY-BASEL 2002;63 (Suppl. 1):33-38 [PubMed]
  • van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen AT, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R, A gene-expression signature as a predictor of survival in breast cancer. NEW ENGL J MED 2002;347 (25):1999-2009 [PubMed]
  • van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH, Gene expression profiling predicts clinical outcome of breast cancer. NATURE 2002;415 (6871):530-536 [PubMed]

2001

  • Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ, Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J CLIN ONCOL 2001;19 (8):2263-2271 [PubMed]
  • Bijker N, Peterse JL, Duchateau L, Robanus-Maandag EC, Bosch CA, Duval C, Pilotti S, van de Vijver MJ, Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. BRIT J CANCER 2001;84 (4):539-544 [PubMed]
  • de Bock GH, Tollenaar RA, Papelard H, Cornelisse CJ, Devilee P, van de Vijver MJ, Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. BRIT J CANCER 2001;85 (9):1347-1350 [PubMed]
  • Elkhuizen PH, Hermans J, Leer JW, van de Vijver MJ, Isolated late local recurrences with high mitotic count and early local recurrences following breast-conserving therapy are associated with increased risk on distant metastasis. INT J RADIAT ONCOL 2001;50 (2):387-396 [PubMed]
  • Faneyte IF, Kristel PM, van de Vijver MJ, Determining MDR1/P-glycoprotein expression in breast cancer. INT J CANCER 2001;93 (1):114-122 [PubMed]
  • Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van de Vijver MJ, Scheper RJ, Schellens JH, Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. CANCER RES 2001;61 (8):3458-3464 [PubMed]
  • Roeleveld TA, Horenblas S, Meinhardt W, van de Vijver M , Kooi M, ten Bokkel Huinink WW, Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J UROLOGY 2001;166 (6):2166-2170 [PubMed]
  • van de Vijver MJ, Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). EUR J CANCER 2001;37 (Suppl. 1):S11-S17 [PubMed]

2000

  • de Bree E, Witkamp A, van de Vijver M , Zoetmulde F, Unusual origins of Pseudomyxoma peritonei. J SURG ONCOL 2000;75 (4):270-274 [PubMed]
  • Elkhuizen PH, van Slooten HJ, Clahsen PC, Hermans J, van de Velde CJ, van den Broek LC, van de Vijver MJ, High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J CLIN ONCOL 2000;18 (5):1075-1083 [PubMed]
  • Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, van de Vijver MJ, Fleuren GJ, Trimbos JB, Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?. GYNECOL ONCOL 2000;77 (1):164-170 [PubMed]
  • Hamilton A, Larsimont D, Paridaens R, Drijkoningen M, van de Vijver M , Bruning P, Hanby A, Houston S, Treilleux I, Guastalla JP, van Vreckem A, Sylvester R, Piccart M, A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. CLIN BREAST CANCER 2000;1 (3):233-40; discussion 241-2 [PubMed]
  • Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ, Koh EY, Daley GQ, van Lohuizen M, Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. NAT GENET 2000;26 (3):291-299 [PubMed]
  • Kenter GG, Hellebrekers BW, Zwinderman KH, van de Vijver M , Peters LA, Trimbos JB, The case for completing the lymphadenectomy when positive lymph nodes are found during radical hysterectomy for cervical carcinoma. ACTA OBSTET GYN SCAN 2000;79 (1):72-76 [PubMed]
  • Kersemaekers AM, van de Vijver MJ, Fleuren GJ, Comparison of the genetic alterations in two epithelial collision tumors of the uterine cervix. A report of two cases. INT J GYNECOL PATHOL 2000;19 (3):225-230 [PubMed]
  • Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Futreal PA, Peto J, Stoppa-Lyonnet D, Bignon YJ, Stratton MR, The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. CLIN CANCER RES 2000;6 (3):782-789 [PubMed]
  • Mandard AM, Denoux Y, Herlin P, Duigou F, van de Vijver MJ, Clahsen PC, van den Broek L, Sahmoud TM, Henry-Amar M, van de Velde CJ, Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density. CANCER-AM CANCER SOC 2000;89 (8):1748-1757 [PubMed]
  • van den Broek LJ, van de Vijver MJ, Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections. APPL IMMUNOHISTO M M 2000;8 (4):316-321 [PubMed]

1999

  • Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, van de Vijver MJ, The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. EJSO-EUR J SURG ONC 1999;25 (4):356-363 [PubMed]
  • Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van Houwelingen HC, Leer JW, van de Vijver MJ, Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. INT J RADIAT ONCOL 1999;45 (1):73-83 [PubMed]
  • Kersemaekers AM, Fleuren GJ, Kenter GG, van den Broek LJ, Uljee SM, Hermans J, van de Vijver MJ, Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. CLIN CANCER RES 1999;5 (3):577-586 [PubMed]
  • Kersemaekers AM, van de Vijver MJ, Kenter GG, Fleuren GJ, Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. GENE CHROMOSOME CANC 1999;26 (4):346-354 [PubMed]
  • Krul EJT, van de Vijver MJ, Schuuring E, van Kanten RW, Peters AAW, Fleuren GJ, Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to the Netherlands, a low-risk country. INT J GYNECOL CANCER 1999;9 (3):206-211 [PubMed]
  • Snijders-Keilholz A, Hellebrekers BW, Zwinderman AH, van de Vijver MJ, Trimbos JB, Adjuvant radiotherapy following radical hysterectomy for patients with early-stage cervical carcinoma (1984-1996). RADIOTHER ONCOL 1999;51 (2):161-167 [PubMed]
  • van de Vijver MJ, The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era: historical perspectives. BREAST CANCER RES 1999;1 (1):27-30 [PubMed]
  • van Slooten HJ, van de Vijver MJ, Borresen AL, Eyfjörd JE, Valgardsdóttir R, Scherneck S, Nesland JM, Devilee P, Cornelisse CJ, van Dierendonck JH, Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma. J PATHOL 1999;189 (4):504-513 [PubMed]
  • Voogd AC, Peterse JL, Crommelin MA, Rutgers EJ, Botke G, Elkhuizen PH, van Geel AN, Hoekstra CJ, van Pel R, van de Vijver MJ, Coebergh JW, Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST). EUR J CANCER 1999;35 (13):1828-1837 [PubMed]
  • Vos CB, ter Haar NT, Peterse JL, Cornelisse CJ, van de Vijver MJ, Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J PATHOL 1999;187 (3):279-284 [PubMed]
  • Vos CB, ter Haar NT, Rosenberg C, Peterse JL, Cleton-Jansen AM, Cornelisse CJ, van de Vijver MJ, Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. BRIT J CANCER 1999;81 (8):1410-1418 [PubMed]
  • Zonderland HM, Coerkamp EG, Hermans J, van de Vijver MJ, van Voorthuisen AE, Diagnosis of breast cancer: contribution of US as an adjunct to mammography. RADIOLOGY 1999;213 (2):413-422 [PubMed]

1998

  • Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ, p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J CLIN ONCOL 1998;16 (2):470-479 [PubMed]
  • Elkhuizen PH, van de Vijver MJ, Hermans J, Zonderland HM, van de Velde CJ, Leer JW, Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. INT J RADIAT ONCOL 1998;40 (4):859-867 [PubMed]
  • Kersemaekers AM, Hermans J, Fleuren GJ, van de Vijver MJ, Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. BRIT J CANCER 1998;77 (2):192-200 [PubMed]
  • Kersemaekers AM, Kenter GG, Hermans J, Fleuren GJ, van de Vijver MJ, Allelic loss and prognosis in carcinoma of the uterine cervix. INT J CANCER 1998;79 (4):411-417 [PubMed]
  • Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Stratton MR, Easton DF, Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. JNCI-J NATL CANCER I 1998;90 (15):1138-1145 [PubMed]
  • van de Vijver MJ, Ductal carcinoma in situ of the breast: histological classification and genetic alterations. RECENT RESULTS CANCER RES 1998;152:123-134 [PubMed]
  • van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH, Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. BRIT J CANCER 1998;77 (5):789-796 [PubMed]

1997

  • Cornelis RS, van Vliet M, van de Vijver MJ, Vasen HF, Voute PA, Top B, Khan PM, Devilee P, Cornelisse CJ, Three germline mutations in the TP53 gene. HUM MUTAT 1997;9 (2):157-163 [PubMed]
  • de Leeuw WJ, Berx G, Vos CB, Peterse JL, van de Vijver MJ, Litvinov S, van Roy F, Cornelisse CJ, Cleton-Jansen AM, Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J PATHOL 1997;183 (4):404-411 [PubMed]
  • Veenhuizen RB, Ruevekamp MC, Oppelaar H, Ransdorp B, van de Vijver M , Helmerhorst TJ, Kenemans P, Stewart FA, Intraperitoneal photodynamic therapy: comparison of red and green light distribution and toxicity. PHOTOCHEM PHOTOBIOL 1997;66 (3):389-395 [PubMed]
  • Vos CB, Cleton-Jansen AM, Berx G, de Leeuw WJ, ter Haar NT, van Roy F, Cornelisse CJ, Peterse JL, van de Vijver MJ, E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. BRIT J CANCER 1997;76 (9):1131-1133 [PubMed]

1996

  • van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ, Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. BRIT J CANCER 1996;74 (1):78-85 [PubMed]
  • Zonderland HM, van de Velde CJ, van de Vijver MJ, Hermans J, Preoperatieve naaldbiopsie: een aanwinst bij palpabele mammatumoren met sterke aanwijzingen voor maligniteit. NED TIJDSCHR GENEESKD 1996;140 (39):1952-1956 [PubMed]

1995

  • Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M , Cornelisse C, van Roy F, E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995;14 (24):6107-6115 [PubMed]

1994

  • Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Børresen AL, Cornelisse CJ, Devilee P, Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. CANCER RES 1994;54 (15):4200-4206 [PubMed]
  • Devilee P, Schuuring E, van de Vijver MJ, Cornelisse CJ, Recent developments in the molecular genetic understanding of breast cancer. CRIT REV ONCOG 1994;5 (2-3):247-270 [PubMed]
  • Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B, Ductal carcinoma in situ: a proposal for a new classification. SEMIN DIAGN PATHOL 1994;11 (3):167-180 [PubMed]

1993

  • van de Vijver MJ, Molecular genetic changes in human breast cancer. ADV CANCER RES 1993;61:25-56 [PubMed]

1992

  • Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, Thunnissen FB, Devilee P, Cornelisse CJ, van de Vijver MJ, Mooi WJ, Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. CANCER RES 1992;52 (19):5229-5234 [PubMed]

1991

  • Beerman H, Bonsing BA, van de Vijver MJ, Hermans J, Kluin PM, Caspers RJ, van de Velde CJ, Cornelisse CJ, DNA ploidy of primary breast cancer and local recurrence after breast-conserving therapy. BRIT J CANCER 1991;64 (1):139-143 [PubMed]
  • van de Vijver MJ, Kumar R, Mendelsohn J, Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J BIOL CHEM 1991;266 (12):7503-7508 [PubMed]
  • van de Vijver MJ, Nusse R, The molecular biology of breast cancer. BBA-REV CANCER 1991;1072 (1):33-50 [PubMed]

1990

  • Schuuring E, van der Leede BJ, Willems R, Daams H, van der Valk M, van de Vijver M , van Leeuwen F, Sonnenberg A, Nusse R, Differentiation-dependent expression of provirus-activated int-1 oncogene in clonal cell lines derived from a mouse mammary tumor. ONCOGENE 1990;5 (4):459-465 [PubMed]
  • van Leeuwen F, van de Vijver MJ, Lomans J, van Deemter L, Jenster G, Akiyama T, Yamamoto T, Nusse R, Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies. ONCOGENE 1990;5 (4):497-503 [PubMed]

1989

  • de Potter CR, van Daele S, van de Vijver MJ, Pauwels C, Maertens G, de Boever J, Vandekerckhove D, Roels H, The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. HISTOPATHOLOGY 1989;15 (4):351-362 [PubMed]

1988

  • van de Vijver MJ, Mooi WJ, Peterse JL, Nusse R, Amplification and over-expression of the neu oncogene in human breast carcinomas. EJSO-EUR J SURG ONC 1988;14 (2):111-114 [PubMed]
  • van de Vijver MJ, Mooi WJ, Wisman P, Peterse JL, Nusse R, Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. ONCOGENE 1988;2 (2):175-178 [PubMed]
  • van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R, Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. NEW ENGL J MED 1988;319 (19):1239-1245 [PubMed]

1987

  • van de Vijver M , van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R, Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. MOL CELL BIOL 1987;7 (5):2019-2023 [PubMed]

1983

  • Bartelink H, van Dongen JA, van Dam FS, van de Vijver M, Borstsparende behandeling bij het operabele mammacarcinoom; eerste beoordeling van de resultaten. NED TIJDSCHR GENEESKD 1983;127 (49):2223-2228 [PubMed]

1977

  • Fevery J, van de Vijver M , Michiels R, Heirwegh KP, Comparison in different species of biliary bilirubin-IX alpha conjugates with the activities of hepatic and renal bilirubin-IX alpha-uridine diphosphate glycosyltransferases. BIOCHEM J 1977;164 (3):737-746 [PubMed]

1972

  • Fevery J, Leroy P, van de Vijver M , Heirwegh KP, Structures of bilirubin conjugates synthesized in vitro from bilirubin and uridine diphosphate glucuronic acid, uridine diphosphate glucose or uridine diphosphate xylose by preparations from rat liver. BIOCHEM J 1972;129 (3):635-644 [PubMed]
  • Heirwegh KP, van de Vijver M , Fevery J, Assay and properties of dititonin-activated bilirubin uridine diphosphate glucuronyltransferase from rat liver. BIOCHEM J 1972;129 (3):605-618 [PubMed]
  • Mertens BB, van de Vijver M , Heirwegh KP, Determination of bilirubin in liver homogenate with diazotized p-iodoaniline. Improvement of color recovery by incorporation of antioxidant (2,6-di-tert-butyl-p-cresol) in the reaction system. ANAL BIOCHEM 1972;50 (2):652-655 [PubMed]